Genmab A/S American Depositary Shares (GMAB1N)

Profile

https://www.genmab.com

Genmab A/S Sponsored ADR represents ownership interests in Genmab A/S, a biotechnology company focused on developing and commercializing antibody-based therapies, primarily for oncology and other serious diseases. The company specializes in innovative antibody platforms, including proprietary technologies such as DuoBody, HexaBody, DuoHexaBody, and HexElect, which are designed to enhance the precision and efficacy of targeted treatments. Genmab plays a significant role in the healthcare sector through a partnership-driven model, collaborating with large pharmaceutical companies to bring its therapies to market. Key marketed therapies derived from Genmab’s technologies include treatments for multiple myeloma, thyroid eye disease, relapsing multiple sclerosis, non-small cell lung cancer, cervical cancer, and diffuse large B-cell lymphoma. Headquartered in Copenhagen, Denmark, and founded in 1999, Genmab today is positioned as an important contributor to the global biotechnology industry, with its antibody platforms integrated across multiple therapeutic areas and commercial collaborations worldwide.